This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jensen, P. B. Articles by Hansen, H. H. Search for Related Content PubMed PubMed Citation Articles by Jensen, P. B. Articles by Hansen, H. H.

Antagonistic Effect of Aclarubicin on Daunorubicin-induced Cytotoxicity in Human Small Cell Lung Cancer Cells: Relationship to DNA Integrity and Topoisomerase II¹

Department of Oncology, The Finsen Institute, DK-2100 Copenhagen Ø [P. B. J., H. H. H.]; Department of Molecular Biology and Plant Physiology, University of Aarhus, DK-8000 Aarhus C [P. S. J., B. S. S., O. W.]; Department of Biochemistry C, Panum Institute, University of Copenhagen, DK-2200 Copenhagen N [E. J. F. D.]; Department of Haematology, Rigshospitalet, DK-2100 Copenhagen Ø [E. F., L. V.]; Department of Pathology, Rigshospitalet, DK-2100 Copenhagen Ø [M. S.]; and Department of Biology and Toxicology, Danish National Institute of Occupational Health, Copenhagen [K. W.], Denmark

The effect of combinations of the anthracyclines aclarubicin and daunorubicin was investigated in a clonogenic assay using the human small cell lung cancer cell line OC-NYH and a multidrug-resistant (MDR) murine subline of Ehrlich ascites tumor (EHR2/DNR+). It was found that the cytotoxicity of daunorubicin in OC-NYH cells was antagonized by simultaneous exposure to nontoxic concentrations of aclarubicin. Coordinately, aclarubicin inhibited the formation of daunorubicin-induced protein-concealed DNA single-strand breaks and DNA-protein cross-links in OC-NYH cells when assayed by the alkaline elution technique. Aclarubicin had no influence on the accumulation of daunorubicin in these cells. In contrast, the accumulation of daunorubicin in EHR2/DNR+ cells was enhanced by more than 300% when the cells were simultaneously incubated with the MDR modulator verapamil, aclarubicin, or the two agents combined. Yet the cytotoxicity of daunorubicin was potentiated significantly only by verapamil. The increased cytotoxicity of daunorubicin in the presence of verapamil was completely antagonized when aclarubicin was used together with the MDR modulator. Finally, the effect of daunorubicin on the DNA cleavage activity of purified topoisomerase II in the presence and absence of aclarubicin was examined. It was found that daunorubicin stimulated DNA cleavage by topoisomerase II at specific DNA sites. The addition of aclarubicin completely inhibited the daunorubicin-induced stimulation of DNA cleavage. Taken together, these data indicate that aclarubicin-mediated inhibition of daunorubicin-induced cytotoxicity is due mainly to a drug interaction with the nuclear enzyme topoisomerase II. This antagonism at the nuclear level explains why aclarubicin is a poor modulator of daunorubicin resistance even though aclarubicin is able to increase the intracellular accumulation of daunorubicin in a MDR cell line.

¹ Supported by grants from the Danish Cancer Society, the Danish Medical Research Council, the Aarhus University Bioregulation Center, the Danish National Agency of Technology, and the Lundbeck Foundation.

² To whom requests for reprints should be addressed, at the Department of Oncology, The Finsen Institute, 49 Strandboulevarden, DK-2100 Copenhagen, Denmark.

Received 10/16/90. Accepted 7/17/91.

This article has been cited by other articles:

				Y. Qin, L. Meng, C. Hu, W. Duan, Z. Zuo, L. Lin, X. Zhang, and J. Ding Gambogic acid inhibits the catalytic activity of human topoisomerase II{alpha} by binding to its ATPase domain Mol. Cancer Ther., September 1, 2007; 6(9): 2429 - 2440. [Abstract] [Full Text] [PDF]

				K. Umemura, T. Mizushima, H. Katayama, Y. Kiryu, T. Yamori, and T. Andoh Inhibition of DNA Topoisomerases II and/or I by Pyrazolo[1,5-a]indole Derivatives and Their Growth Inhibitory Activities Mol. Pharmacol., October 1, 2002; 62(4): 873 - 880. [Abstract] [Full Text] [PDF]

				L. H. Jensen, A. Renodon-Corniere, I. Wessel, S. W. Langer, B. Sokilde, E. V. Carstensen, M. Sehested, and P. B. Jensen Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition Mol. Pharmacol., May 1, 2002; 61(5): 1235 - 1243. [Abstract] [Full Text] [PDF]

				L. H. Jensen, K. C. Nitiss, A. Rose, J. Dong, J. Zhou, T. Hu, N. Osheroff, P. B. Jensen, M. Sehested, and J. L. Nitiss A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines J. Biol. Chem., January 21, 2000; 275(3): 2137 - 2146. [Abstract] [Full Text] [PDF]

				B. B. Hasinoff, A. M. Creighton, H. Kozlowska, P. Thampatty, W. P. Allan, and J. C. Yalowich Mitindomide Is a Catalytic Inhibitor of DNA Topoisomerase II That Acts at the Bisdioxopiperazine Binding Site Mol. Pharmacol., November 1, 1997; 52(5): 839 - 845. [Abstract] [Full Text]